Epilepsy in Alternating Hemiplegia of Childhood: Characteristics, Neuroimaging, and Response to Therapy (P4.6-069)
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: Describe the manifestations of epilepsy in Alternating Hemiplegia of Childhood (AHC) and our experience in managing it.
Background: AHC is characterized by recurrent episodes of hemiplegia, double hemiplegia, dystonia, and, frequently, epilepsy. However, the characteristics of epilepsy in AHC have yet to be described in detail.
Design/Methods: We analyzed clinical and electrophysiological data of a cohort of 50 consecutive AHC patients who underwent systematic evaluations as per our clinical pathway.
Results: 31/50 had epilepsy (seizure age of onset: 1.89±3.04 years). In seven, seizures preceded other AHC spells. Eighteen (58%) were drug resistant. Seventeen had focal seizures, frontal more frequently than temporal, then parietal, and occipital. Eleven had primary generalized seizures: 11 generalized tonic-clonic (GTC), 3 myoclonic, and 2 absence. Three had GTCs of unknown onset. Therapies included antiepileptics (31/31), ketogenic diet (6/31), repurposed drugs (11/31) and pulse steroids (2/31), and had mixed results. Vagal nerve stimulation resulted in >50% reduction in seizure frequency in 5/6. Although the majority had epileptiform EEGs, 7 initially had normal EEGs that later became epileptiform. MRI, normal in the majority, showed in some cerebral atrophy (3/31), cerebellar atrophy (3/31) or abnormal spectroscopy (4/5, all had prior status epilepticus-SE). Eleven (35%) had SE, refractory or super refractory in all. 8/11 had multiple SE episodes. 3/11 had regression after SE.26/50 also had, previously not characterized, spells we termed Reduced Awareness Spells (RAS), consisting of isolated lethargy, drowsiness, staring, and reduced responsiveness without concomitant clinical epileptic manifestations or EEG changes.
Conclusions: Epilepsy in AHC: 1) is focal or generalized, 2) can be the initial manifestation of AHC, 3) manifests high frequency of drug resistance and of often recurrent refractory SE that at times is followed by regression, and 4) RAS, likely non-epileptic in nature, occur frequently.
Disclosure: Dr. Uchitel has nothing to disclose. Dr. Helseth has nothing to disclose. Dr. Prange has nothing to disclose. Dr. McLean has nothing to disclose. Dr. Ghusayni has nothing to disclose. Dr. Sachdev has nothing to disclose. Dr. Hunanyan has nothing to disclose. Dr. Mikati has nothing to disclose.
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within the last 8 weeks.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.